<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542879</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-20221</org_study_id>
    <secondary_id>IRB-20221</secondary_id>
    <secondary_id>PEDSVAR0017</secondary_id>
    <nct_id>NCT01542879</nct_id>
  </id_info>
  <brief_title>Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer</brief_title>
  <official_title>Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heike E Daldrup-Link</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study on the diagnosis of spread of disease for children who have been diagnosed
      with solid tumors using a new whole body imaging technique and a new MR contrast agent
      (ferumoxytol). Standard tests that are used to determine the extent and possible spread of a
      child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron
      Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG)
      scanning. The purpose of this study is to determine if newer imaging tests referred to as
      whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of
      the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The
      advantage of the new imaging test is that it is associated with no or significantly reduced
      radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole
      body MR and PET/MR will be compared with that of the conventional, standard imaging studies
      for tumor detecting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To compare the sensitivity, specificity and accuracy of WB-DW-MR scans
      (new technique) with 18F- FDG PET or 18F- FDG PET/CT or 18F- FDG PET/MR scans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of sensitivity, specificity and accuracy of WB-DW-MR scans to 18-F FDG PET scans.</measure>
    <time_frame>The outcome will be measured after image acquisition</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of sensitivity, specificity and accuracy of Ferumoxytol-enhanced whole-body 18-F FDG PET/MR-scans versus standard clinical Gadolinium-enhanced whole-body 18-F FDG PET/MR-scans.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>WB-DW-MR scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>simultaneous WB-DW-MR scan and 18-F FDG PET scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>WB-DW-MR scan</intervention_name>
    <description>WB-DW-MR scans will be obtained on a 3T PET-MR system</description>
    <arm_group_label>WB-DW-MR scan</arm_group_label>
    <other_name>Whole Body Diffusion Weighted MR scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>18-F-FDG PET scan</intervention_name>
    <arm_group_label>WB-DW-MR scan</arm_group_label>
    <other_name>Fludeoxyglucose PET scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <arm_group_label>WB-DW-MR scan</arm_group_label>
    <other_name>feraheme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>18-F-FDG PET/MR scan</intervention_name>
    <arm_group_label>WB-DW-MR scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a solid extra-cranial tumor like malignant lymphoma or malignant sarcoma
             and

          -  Scheduled for or completed a 18F-FDG-PET or 18F-FDG-PET/CT tumor staging procedure.

          -  There will be no restrictions on prior treatment.

          -  Very young children who need sedation or anesthesia will be excluded from the study.

          -  In this pediatric &amp; adult study, the participant or parent/guardian is consented, and
             the patient when a minor is given an assent form and involved in the discussion as
             appropriate.

        Exclusion Criteria:

          -  MR-incompatible metal implants,

          -  need of sedation or claustrophobia.

          -  Hemosiderosis/hemochromatosis (patients can still be included in 2nd branch without
             ferumoxytol)

          -  There will be restrictions regarding use of other Investigational Agents: Pt with
             iron-overload will not receive Ferumoxytol

          -  History of allergic reactions to similar compounds will be obtained and patients with
             a positive history of allergic reaction to iron compounds or other severe allergic
             reactions.will be excluded from the study.

          -  Pregnant women and fetuses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Daldrup-Link</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brittney Williams</last_name>
    <phone>650-497-8588</phone>
    <email>bw718@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kangla Tsung</last_name>
      <phone>650-725-8198</phone>
      <email>tsungk@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Heike Daldrup-Link, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Quon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neyssa Marina</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florette Kimberley Hazard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dita Gratzinger</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Muehe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>February 8, 2020</last_update_submitted>
  <last_update_submitted_qc>February 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Heike E Daldrup-Link</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

